Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at Needham & Company
August 5, 2021 6:30 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "ACAD reported $115.2M in 2Q21 Nuplazid sales, below our $130.0M and consensus $126.3M ests. Sales +vely impacted by volume... More
